Global Newswire by Notified: M&A

DECEMBER 13, 2024

Palvella Therapeutics to debut on Nasdaq under the ticker symbol PVLA as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a platform for treating serious, rare genetic diseases

Pharmaceutical 45

Pharmaceutical Public Trading Mergers Trading 45

TM Capital

JULY 17, 2024

Josh has extensive experience completing transactions across key healthcare services sectors including physician practice management, ambulatory surgery centers, and pharmaceutical services.

Capital 52

Capital Pharmaceutical Private Equity Healthcare 52

Cooley M&A

OCTOBER 19, 2022

Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals. Lavoro to Become Publicly Traded Through Business Combination With TPB Acquisition Corporation I. TCGplayer Agrees to Sell to eBay. DigitalOcean Agrees to Buy Cloudways. Sixth Street Invests in Blueprint Medicines.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 22, 2020

A wave of big-ticket transactions by global pharmaceutical companies drove life sciences M&A activity to its fourth-largest year on record in 2019, with aggregate deal value in the pharmaceutical, medical and biotech industry reaching $234.2 2019 was a banner year for billion-dollar life sciences M&A transactions.

M&A 40

M&A Pharmaceutical Acquisitions Capital 40

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 20, 2022

1] Major all-cash acquisitions have followed, such as Arena Pharmaceutical’s agreement to sell to Pfizer for $6.7 Midsize pharmaceutical buyers pursuing opportunistic acquisition strategies, with robust capital markets and high valuations having limited the pool of attractive assets available in recent years.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Mergers 40

Focus Investment Banking

DECEMBER 20, 2024

Cencora, one of the largest publicly-traded pharmaceutical companies in the world, distributes pharmaceuticals, over-the-counter healthcare products and other healthcare supplies and equipment to healthcare providers. In RCA, Cencora saw the opportunity to acquire additional profitability downstream of its existing operations.

Private Equity 52

Private Equity Healthcare Equities Sale 52